mk-8583

MK-8583 is a novel tenofovir prodrug developed as an oral nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV-1 infection. It is designed to deliver tenofovir diphosphate, the active metabolite, with a long intracellular half-life that could potentially enable weekly dosing. MK-8583 acts by inhibiting HIV reverse transcriptase, thereby blocking viral replication. In clinical studies, MK-8583 demonstrated rapid absorption and elimination from plasma but maintained prolonged levels of its active metabolite in peripheral blood mononuclear cells. Despite achieving pharmacologically relevant concentrations, reductions in HIV viral load were suboptimal compared to existing therapies. The drug was developed and tested primarily by Merck Sharp & Dohme.